Physician profile
Jonathan King
NPI 1033789763
$42,148.97
in general payments reported to CMS, 2019-2025
15 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $6,744 · 2023: $4,297 · 2024: $5,629 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $24K · Travel and Lodging: $6,901 · Consulting Fee: $2,592 · Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $24,150.00 |
| Travel and Lodging | $6,900.57 |
| Consulting Fee | $2,591.67 |
| Food and Beverage | $1,153.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $36,673.45 | 2022-2025 | Zenlens, Xiidra, Miebo |
| Valley Contax, INC. | $3,470.56 | 2022 | |
| Alcon Vision LLC | $533.60 | 2021-2025 | Total30, Precision7 |
| Coopervision INC. | $428.25 | 2021-2025 | Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $406.67 | 2021-2022 | |
| Abbvie INC. | $152.40 | 2023-2025 | |
| Amgen INC. | $138.56 | 2024-2025 | Krystexxa, Tepezza |
| Oyster Point Pharma, INC. | $98.56 | 2022 | |
| Allergan, INC. | $77.95 | 2022 | |
| Glaukos Corporation | $46.31 | 2022 | |
| Dompe US, INC. | $45.21 | 2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $25.68 | 2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $19.47 | 2025 | Xdemvy |
| Harrow Eye, LLC | $17.96 | 2025 | Iheezo |
| Rxsight INC | $14.34 | 2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.